Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 5/20 | 0.76 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.76 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.76 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.76 |
| ▸ | CNR1 | P21554 | 2/20 | 0.73 |
| ▸ | CNR2 | P34972 | 2/20 | 0.73 |
| ▸ | DGKA | P23743 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29644755 | 1.00 | PRKCA (0.76) | PRKCAPRKCEPRKCQPRKCDCNR1 | |
| SCHEMBL27611141 | 1.00 | PRKCA (0.76) | PRKCAPRKCEPRKCQPRKCDCNR1 | |
| SCHEMBL7557200 | 1.00 | PRKCA (0.76) | PRKCAPRKCEPRKCQPRKCDCNR1 | |
| SCHEMBL30524570 | 1.00 | PRKCA (0.76) | PRKCAPRKCEPRKCQPRKCDCNR1 | |
| SCHEMBL6479094 | 1.00 | PRKCA (0.76) | PRKCAPRKCEPRKCQPRKCDCNR1 | |
| SCHEMBL7557194 | 1.00 | PRKCA (0.76) | PRKCAPRKCEPRKCQPRKCDCNR1 | |
| SCHEMBL10492119 | 1.00 | PRKCA (0.76) | PRKCAPRKCEPRKCQPRKCDCNR1 | |
| SCHEMBL1145297 | 1.00 | PRKCA (0.76) | PRKCAPRKCEPRKCQPRKCDCNR1 | |
| SCHEMBL5407956 | 0.96 | CNR1 (0.80) | PRKCAPRKCEPRKCQPRKCDCNR1 | |
| SCHEMBL3495835 | 0.96 | CNR1 (0.80) | PRKCAPRKCEPRKCQPRKCDCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023238837-A1 | EXOSOME COMPLEX AND MANUFACTURING METHOD THEREOF | JSR株式会社 | 2023-12-14 | — | — | WO | disclosed |
| US-10000791-B2 | Measurement method for human pancreatic lipase activity | ASAHI KASEI PHARMA CORPORATION (JP) | 2018-06-19 | — | — | US | disclosed |
| EP-2987867-B1 | METHOD FOR MEASURING ACTIVITY OF HUMAN PANCREATIC LIPASE | ASAHI KASEI PHARMA CORP (JP) | 2017-11-08 | — | — | EP | disclosed |
| EP-2987867-A1 | METHOD FOR MEASURING ACTIVITY OF HUMAN PANCREATIC LIPASE | Asahi Kasei Pharma Corporation (JP) | 2016-02-24 | — | — | EP | disclosed |
| US-20160024553-A1 | MEASUREMENT METHOD FOR HUMAN PANCREATIC LIPASE ACTIVITY | ASAHI KASEI PHARMA CORPORATION (JP) | 2016-01-28 | — | — | US | disclosed |
| EP-1813680-B1 | COMPOSITIONS FOR LIPASE ACTIVITY DETERMINATION AND METHOD OF DETERMINING ACTIVITY | ASAHI KASEI PHARMA CORP (JP) | 2011-11-09 | — | — | EP | disclosed |
| US-7883862-B2 | comprising at least one diglyceride, a low concentration buffer, and a nonionic surfactant; for determining activity of pancreatic lipase or non-pancreatic lipases (such as hepatic lipase or lipoprotein lipase) in clinical laboratory tests | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-02-08 | — | — | US | disclosed |
| US-20080038765-A1 | Composition for Lipase Activity Determination and Method of Determing Activity | ASAHI KASEI PHARMA CORPORATION (JP) | 2008-02-14 | — | — | US | disclosed |
| EP-1813680-A1 | COMPOSITIONS FOR LIPASE ACTIVITY DETERMINATION AND METHOD OF DETERMINING ACTIVITY | Asahi Kasei Pharma Corporation (JP) | 2007-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080038765-A1 | Composition for Lipase Activity Determination and Method of Determing Activity | LPL, GK, LIPG | PRKCA 231/4885PRKCE 456/4885PRKCQ 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.